| Literature DB >> 28935963 |
Miska Sulkava1, Emma Raitoharju2, Ari Mennander3, Mari Levula2, Ilkka Seppälä2, Leo-Pekka Lyytikäinen2, Otso Järvinen3, Thomas Illig4,5,6, Norman Klopp4,5, Nina Mononen2, Reijo Laaksonen2, Mika Kähönen7, Niku Oksala2,3, Terho Lehtimäki2.
Abstract
Ascending thoracic aortic aneurysm (ATAA) is a multifactorial disease with a strong inflammatory component. Surgery is often required to prevent aortic rupture and dissection. We performed gene expression analysis (Illumina HumanHT-12 version 3 Expression BeadChip) for 32 samples from ATAA (26 without/6 with dissection), and 28 left internal thoracic arteries (controls) collected in Tampere Vascular study. We compared expression profiles and conducted pathway analysis using Ingenuity Pathway Analysis (IPA) to reveal differences between ATAA and a healthy artery wall. Almost 5000 genes were differentially expressed in ATAA samples compared to controls. The most downregulated gene was homeobox (HOX) A5 (fold change, FC = -25.3) and upregulated cadherin-2 (FC = 12.6). Several other HOX genes were also found downregulated (FCs between -25.3 and -1.5, FDR < 0.05). 43, mostly inflammatory, canonical pathways in ATAA were found to be significantly (p < 0.05, FDR < 0.05) differentially expressed. The results remained essentially the same when the 6 dissected ATAA samples were excluded from the analysis. We show for the first time on genome level that ATAA is an inflammatory process, revealing a more detailed molecular pathway level pathogenesis. We propose HOX genes as potentially important players in maintaining aortic integrity, altered expression of which might be important in the pathobiology of ATAA.Entities:
Mesh:
Year: 2017 PMID: 28935963 PMCID: PMC5608723 DOI: 10.1038/s41598-017-12421-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographics of the study population.
| Ascending aortic aneurysm | Left internal thoracic artery | |
|---|---|---|
| N | 32 | 28 |
| Age (mean, SD)* | 62.6 (12.9) | 67.3 (9.6) |
| Men (%)* | 71.9 | 82.1 |
| BMI (mean kg/m2, SD) | 28.1 (6.5) | 28.9 (5.1) |
| Smoking (%)* | 43.8 | 64.3 |
| Hypercholesterolemia (%)* | 53.1 | 85.7 |
| Hypertension (%)* | 93.8 | 100.0 |
| Cardiac insufficiency (%)* | 34.4 | 21.4 |
| Statin users (%)* | 41.9 | 82.1 |
| Coronary artery disease (%)* | 21.9 | 100.0 |
| Myocardial infarction (%)* | 9.4 | 39.3 |
| Dissected (aorta) (%) | 18.8 | — |
*Statistically significant difference (p < 0.05). In categorical variables (sex, smoking, hypercholesterolemia, hypertension, cardiac insufficiency, statin user, coronary artery disease and myocardial infarction) p < 0.05 with both chi-square test and Fisher’s exact test. With age and BMI we used independent samples t-test.
The most up- and down-regulated (FC > ± 5) genes in ascending thoracic aorta aneurysm samples when compared to left internal thoracic artery.
| Symbol | Accession | FC | P-value | FDR | Symbol | Accession | FC | P-value | FDR |
|---|---|---|---|---|---|---|---|---|---|
| Down-regulated | Up-regulated | ||||||||
| HOXA5 | NM_019102.2 | −25.3 | 4.59*10−16 | 1.37*10−13 | CDH2 | NM_001792.2 | 12.6 | 9.18*10−16 | 2.01*10−13 |
| ACTA1 | NM_001100.3 | −17.9 | 5.51*10−15 | 7.87*10−13 | CYTL1 | NM_018659.2 | 10.4 | 9.18*10−16 | 2.01*10−13 |
| RGS7BP | NM_001029875.1 | −14.7 | 4.59*10−16 | 1.37*10−13 | SCG2 | NM_003469.3 | 10.2 | 9.18*10−16 | 2.01*10−13 |
| PTCHD1 | NM_173495.2 | −13.4 | 4.59*10−16 | 1.37*10−13 | IGLL1 | NM_020070.2 | 9.5 | 2.09*10−8 | 3.42*10−7 |
| HOXC6 | NM_004503.3 | −13.4 | 4.59*10−16 | 1.37*10−13 | RPRML | NM_203400.1 | 8.8 | 1.71*10−13 | 1.26*10−11 |
| LOC285016 | NM_001002919.1 | −12.1 | 4.59*10−16 | 1.37*10−13 | COL21A1 | NM_030820.2 | 8.2 | 1.84*10−15 | 3.42*10−13 |
| HOXC8 | NM_022658.3 | −11.7 | 4.59*10−16 | 1.37*10−13 | LOC652694 | XM_942302.1 | 8.1 | 5.13*10−9 | 9.77*10−8 |
| MUSTN1 | NM_205853.2 | −11 | 8.73*10−15 | 1.13*10−12 | LOC652493 | XM_941953.1 | 7.8 | 1.59*10−8 | 2.68*10−7 |
| RBPMS2 | NM_194272.1 | −10.4 | 4.59*10−16 | 1.37*10−13 | IGJ | NM_144646.2 | 7.8 | 9.66*10−7 | 9.86*10−6 |
| SEMA3E | NM_012431.1 | −8.8 | 4.59*10−16 | 1.37*10−13 | C5orf46 | NM_206966.2 | 7.2 | 1.25*10−13 | 9.77*10−12 |
| WFDC1 | NM_021197.2 | −8.5 | 6.38*10−14 | 5.65*10−12 | HAPLN1 | NM_001884.2 | 7.1 | 4.59*10−16 | 1.37*10−13 |
| FZD3 | NM_017412.2 | −8.3 | 9.18*10−16 | 2.01*10−13 | IL6 | NM_000600.1 | 6.9 | 1.04*10−5 | 7.64*10−5 |
| HOXA9 | NM_152739.3 | −7.8 | 4.59*10−16 | 1.37*10−13 | LOC647450 | XM_936518.1 | 6.8 | 1.39*10−8 | 2.38*10−7 |
| HBG2 | NM_000184.2 | −7.8 | 3.27*10−5 | 2.05*10−4 | CTHRC1 | NM_138455.2 | 6.6 | 9.18*10−16 | 2.01*10−13 |
| ALAS2 | NM_001037968.1 | −7.5 | 8.09*10−11 | 2.56*10−9 | SPINT2 | NM_021102.2 | 6.3 | 3.21*10−15 | 5.14*10−13 |
| SRL | NM_001098814.1 | −7.5 | 5.51*10−15 | 7.87*10−13 | ARPP−21 | NM_016300.4 | 6.3 | 1.25*10−12 | 6.89*10−11 |
| LEP | NM_000230.1 | −6.8 | 3.45*10−10 | 9.14*10−9 | ATP1B1 | NM_001677.3 | 6.2 | 3.21*10−15 | 5.14*10−13 |
| ABCA6 | NM_080284.2 | −6.7 | 9.18*10−16 | 2.01*10−13 | RPLP1 | NM_001003.2 | 5.8 | 4.59*10−16 | 1.37*10−13 |
| UBN2 | NM_173569.2 | −6.4 | 4.59*10−16 | 1.37*10−13 | IL13RA2 | NM_000640.2 | 5.6 | 3.08*10−14 | 3.06*10−12 |
| CIDEC | NM_022094.2 | −6.2 | 2.53*10−5 | 1.64*10−4 | CAPZA1 | NM_006135.1 | 5.6 | 4.59*10−16 | 1.37*10−13 |
| KIAA1881 | XM_001130790.1 | −6.1 | 5.39*10−6 | 4.34*10−5 | LOC642113 | XM_936253.1 | 5.5 | 6.99*10−7 | 7.42*10−6 |
| FHL5 | NM_020482.3 | −6.1 | 9.18*10−16 | 2.01*10−13 | DNER | NM_139072.3 | 5.5 | 3.03*10−11 | 1.09*10−9 |
| PCDH17 | NM_014459.2 | −6 | 4.59*10−16 | 1.37*10−13 | RAPH1 | NM_213589.1 | 5.4 | 5.51*10−15 | 7.87*10−13 |
| LOC642678 | XM_926130.1 | −5.8 | 4.59*10−16 | 1.37*10−13 | SPP1 | NM_000582.2 | 5.2 | 1.05*10−8 | 1.85*10−7 |
| BTC | NM_001729.1 | −5.8 | 4.59*10−16 | 1.37*10−13 | |||||
| OR51E2 | NM_030774.2 | −5.8 | 4.59*10−16 | 1.37*10−13 | |||||
| ANGPTL5 | NM_178127.2 | −5.8 | 1.25*10−13 | 9.77*10−12 | |||||
| P2RX1 | NM_002558.2 | −5.7 | 3.21*10−15 | 5.14E*10−13 | |||||
| XM_378360 | −5.5 | 4.59*10−16 | 1.37*10−13 | ||||||
| HOXC4 | NM_014620.4 | −5.4 | 4.59*10−16 | 1.37*10−13 | |||||
| PAK2 | XM_001126110.1 | −5.4 | 4.59*10−16 | 1.37*10−13 | |||||
| LOC399888 | XM_941808.2 | −5.2 | 1.25*10−13 | 9.77*10−12 | |||||
| AAK1 | NM_014911.3 | −5.2 | 4.59*10−16 | 1.37*10−13 | |||||
| RORA | NM_002943.2 | −5.1 | 4.59*10−16 | 1.37*10−13 | |||||
| DDX17 | NM_006386.3 | −5.1 | 9.18*10−16 | 2.01*10−13 | |||||
| LOC652726 | XM_942351.2 | −5.1 | 4.59*10−16 | 1.37*10−13 | |||||
The Ingenuity Pathway Analysis results showing the most differentially expressed pathways (FDR < 0.05) in ascending thoracic aorta aneurysm samples when compared to control vessel (LITA).
| Ingenuity Canonical Pathways | FDR* | Ratio | Down-regulated | Up-regulated | |
|---|---|---|---|---|---|
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | 7.08*10−7 | 0.339 | 12/183 (7%) | 50/183 (27%) | |
| Adipogenesis pathway | 1.02*10−5 | 0.351 | 16/134 (12%) | 31/134 (23%) | |
| Role of Macrophages. Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 4.17*10−5 | 0.272 | 19/309 (6%) | 65/309 (21%) | |
| Axonal Guidance Signaling | 4.17*10−4 | 0.241 | 39/448 (9%) | 69/448 (15%) | |
| Integrin Signaling | 9.77*10−4 | 0.274 | 23/219 (11%) | 37/219 (17%) | |
| p53 Signaling | 0.001 | 0.324 | 7/111 (6%) | 29/111 (26%) | |
| Signaling by Rho Family GTPases | 0.00240 | 0.259 | 20/247 (8%) | 44/247 (18%) | |
| Leukocyte Extravasation Signaling | 0.00537 | 0.262 | 19/210 (9%) | 36/210 (17%) | |
| Calcium Signaling | 0.00617 | 0.270 | 23/178 (13%) | 25/178 (14%) | |
| ILK Signaling | 0.00933 | 0.260 | 23/196 (12%) | 28/196 (14%) | |
| Clathrin-mediated Endocytosis Signaling | 0.00955 | 0.259 | 14/197 (7%) | 37/197 (19%) | |
| Ephrin Receptor Signaling | 0.01 | 0.264 | 15/174 (9%) | 31/174 (18%) | |
| RhoA Signaling | 0.01 | 0.287 | 12/122 (10%) | 23/122 (19%) | |
| Regulation of Actin-based Motility by Rho | 0.0102 | 0.308 | 11/91 (12%) | 17/91 (19%) | |
| Complement System | 0.0102 | 0.405 | 1/37 (3%) | 14/37 (38%) | |
| Wnt/Ca + pathway | 0.0102 | 0.351 | 8/57 (14%) | 12/57 (21%) | |
| HMGB1 Signaling | 0.0102 | 0.278 | 6/133 (5%) | 31/133 (23%) | |
| Germ Cell-Sertoli Cell Junction Signaling | 0.0115 | 0.260 | 19/173 (11%) | 26/173 (15%) | |
| RhoGDI Signaling | 0.0115 | 0.260 | 18/173 (10%) | 27/173 (16%) | |
| Neurotrophin/TRK Signaling | 0.0132 | 0.316 | 9/76 (12%) | 15/76 (20%) | |
| Xenobiotic Metabolism Signaling | 0.0132 | 0.234 | 27/286 (9%) | 40/286 (14%) | |
| Glucocorticoid Receptor Signaling | 0.0138 | 0.233 | 19/287 (7%) | 48/287 (17%) | |
| Hypoxia Signaling in the Cardiovascular System | 0.0170 | 0.323 | 6/65 (9%) | 15/65 (23%) | |
| HIF1α Signaling | 0.0170 | 0.278 | 9/115 (8%) | 23/115 (20%) | |
| Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 0.0170 | 0.249 | 14/193 (7%) | 34/193 (18%) | |
| EIF2 Signaling | 0.0179 | 0.247 | 6/194 (3%) | 42/194 (22%) | |
| Assembly of RNA Polymerase I Complex | 0.0179 | 0.667 | 2/9 (22%) | 4/9 (44%) | |
| IL-8 Signaling | 0.0240 | 0.244 | 13/197 (7%) | 35/197 (18%) | |
| mTOR Signaling | 0.0295 | 0.241 | 9/199 (5%) | 39/199 (20%) | |
| VDR/RXR Activation | 0.0324 | 0.295 | 5/78 (6%) | 18/78 (23%) | |
| LXR/RXR Activation | 0.0331 | 0.264 | 9/121 (7%) | 23/121 (19%) | |
| Role of Osteoblasts. Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 0.0331 | 0.233 | 15/232 (6%) | 39/232 (17%) | |
| Actin Cytoskeleton Signaling | 0.0355 | 0.232 | 19/228 (8%) | 34/228 (15%) | |
| Atherosclerosis Signaling | 0.0355 | 0.260 | 6/127 (5%) | 27/127 (21%) | |
| Granulocyte Adhesion and Diapedesis | 0.0355 | 0.243 | 9/177 (5%) | 34/177 (19%) | |
| Role of IL-17F in Allergic Inflammatory Airway Diseases | 0.0355 | 0.341 | 3/44 (7%) | 12/44 (27%) | |
| Pyrimidine Ribonucleotides Interconversion | 0.0372 | 0.375 | 4/32 (13%) | 8/32 (25%) | |
| Huntington’s Disease Signaling | 0.0407 | 0.228 | 20/241 (8%) | 35/241 (15%) | |
| Wnt/β-catenin Signaling | 0.0407 | 0.243 | 15/169 (9%) | 26/169 (15%) | |
| Renal Cell Carcinoma Signaling | 0.0417 | 0.284 | 7/81 (9%) | 16/81 (20%) | |
| Dendritic Cell Maturation | 0.0417 | 0.237 | 11/190 (6%) | 34/190 (18%) | |
| PCP pathway | 0.0417 | 0.302 | 6/63 (10%) | 13/63 (21%) | |
| Antigen Presentation Pathway | 0.0417 | 0.351 | 2/37 (5%) | 11/37 (30%) | |
*FDR-value calculated by the Benjamini-Hochberg –method.